- 基本信息
|
导师姓名：
|
侯健
|
学科代码：
|
100201
|
|
|
性别：
|
男
|
学科名称：
|
内科学
|
|
培养单位：
|
附属仁济医院
|
三级学科
|
血液病
|
|
导师类型：
|
博士生导师
|
专业领域名称：
|
内科学 专业学位
|
|
联系方式：
|
houjian@medmail.com.cn
|
专业领域代码：
|
105101
|
|
邮编：
|
200127
|
邮箱地址：
|
houjian@medmail.com.cn
|
- 研究方向 (点击浏览详细信息)
- 社会任职
| |
|
上海市免疫学会血液免疫分会主任委员
|
|
Chinese Medical Journal 编委
|
|
中国医师协会血液分会常委
|
|
国际骨髓瘤工作组（IMWG）委员
|
|
中国药促会药物临床研究专委会副主委
|
|
中华血液学杂志 等10余本核心期刊 编委
|
|
CSCO中国抗白血病联盟 副主委
|
|
中国免疫学会血液免疫分会常委
|
|
上海医学会血液分会主任委员
|
|
中华医学会血液学分会常委
|
|
CSCO中国抗淋巴瘤联盟常委
|
- 科研项目
| SHDC2020CR2070B | 多发性骨髓瘤新型预后分层及疗效评估体系建立 | 申康三年行动计划重点项目（第二批） |
2021-01~2023-12
|
300万元
| 课题负责人 |
| 81074006 | C反应蛋白调控T淋巴细胞抑制抗骨髓瘤适应性免疫的机制研究 | 国家自然基金 |
2020-01~2023-12
|
55万元
| 课题负责人 |
| XDA12020106-3 | 2. 抗难治性或复发性多发性骨髓瘤新药倍赛诺他的个性化特征研究 | 中国科学院先导科技专项 |
2017-07~2019-12
|
225万元
| 课题负责人 |
- 学术论文
|
Yu-Bo Zhou, Yang-Ming Zhang, Hong-Hui Huang, Li-Jing Shen, Xiao-Feng Han, Xiao-Bei Hu, Song-da Yu, An-Hui Gao, Li Sheng, Ming-Bo Su, Xiao-Li Wei, Yue Zhang, Yi-Fan Zhang , Zhi-Wei Gao, Xiao-Yan Chen, Fa-Jun Nan,, Jian Hou
|
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
|
Acta Pharmacol Sin .
|
2021
|
12(26):223
|
|
He H, Fu W, Du J, Jiang H,
|
Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen.
|
Br J Haematol
|
2018
|
2018 Apr;181(1):126-128.
|
|
Li F, Zhai YP, Lai T, Zhao Q, Zhang H, Tang YM,
|
MB4-2/MB4-3 transcripts of IGH-MMSET fusion gene in t(4;14)pos multiple myeloma indicate poor prognosis.
|
Oncotarget
|
2017
|
2017 May 24;8(31):51608-51620
|
|
, Qiu L, Zhao Y, Zhang X, Liu Y, Wang Z, Zhou F, Leng Y, Yang S, Xi H, Wang F, Zhu B, Chen W, Wei P, Zheng X.
|
A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma.
|
Am J Clin Oncol.
|
2017
|
2017 Sep 19. doi: 10.1097/COC.0000000000000404. [Epub ahead of print]
|
|
, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P
|
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
|
J Hematol Oncol.
|
2017
|
10(1):137.
|
|
Yan W, Li R, He J, Du J,
|
Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
|
Cell Signal
|
2015
|
2015 Apr;27(4):851-9.
|
|
Du J, Liu S, He J, Liu X, Qu Y, Yan W, Fan J, Li R, Xi H,, Zhang C, Yang J, Hou J.
|
MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
|
Oncotarget
|
2015
|
2015 Jun 20;6(17):14993-5007
|
|
Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE, Qian J,, Yi Q
|
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression.
|
Nat Commun.
|
2014
|
2014 Jun 24;5:4229
|
|
Huang HJ, Zhou LL, Fu WJ, Zhang CY, Jiang H, Du J,
|
β-catenin SUMOylation is involved in the dysregulated proliferation of myeloma cells.
|
Am J Cancer Res
|
2014
|
2014 Dec 15;5(1):309-20.
|
|
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.
Li R, Qian J, Zhang W, Fu W, Du J, Jiang H, Zhang H, Zhang C, Xi H, Yi Q,
|
Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma.
|
Br J Haematol.
|
2014
|
2014 Sep;166(5):690-701
|
|
Fan JL, Zhang J, Dong LW, Fu WJ, Du J, Shi HG, Jiang H, Ye F, Xi H, Zhang CY,, Wang HY.
|
URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.
|
Cell Death Dis.
|
2014
|
2014 Mar 13;5:e1126.
|
|
Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, Man-Yuen Sze D, Yi Q, Hou J
|
Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
|
Mol Oncol.
|
2014
|
2014 Mar;8(2):297-310
|
|
, Du X, Jin J, Cai Z, Chen F, Zhou DB, Yu L, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, Wortman-Vayn H, Chen N, Mei J, Wang J
|
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
|
J Hematol Oncol
|
2013
|
2013 Jun 19;6:41
|
|
Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW,, Yi Q
|
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
|
blood
|
2012
|
2012 Jan 5;119(1):161-9.
|
|